Printer Friendly

'REDISCOVERED' 50-YEAR OLD MIGRAINE DRUG AND NEWLY APPROVED THERAPY OFFER NEW HOPE FOR RELIEF FROM HEADACHE PAIN

 BOSTON, Dec. 30 /PRNewswire/ -- On Dec. 29, 1992, U.S. regulatory authorities announced the approval of sumatriptan, an injectable drug for relief of the acute pain of migraine headaches.
 However, recent clinical observations are part of a trend pointing to positive similarities between sumatriptan and a 50-year-old migraine drug that is considerably less expensive. The drug is DHE-45R (dihydroergotamine mosylate) Injection, USP, marketed by Sandoz Pharmaceuticals Corporation. DHE-45 is currently available as an injection. However, Sandoz is waiting for approval to market, in addition, a nasal spray formulation of DHE-45.
 A wave of clinical studies on DHE-45 led the agenda of the most recent annual scientific conference of the American Association for the Study of Headache.
 According to Joel R. Saper, MD, FACP, immediate past president of the American Association for the Study of Headache and director of the Michigan Head Pain and Neurological Institute, "The rediscovery of DHE- 45 and the arrival of sumatriptan, two very similar drugs, are important and welcome developments for migraine sufferers. However, it is important to remember that no drug provides a quick fix or cure all. A wide range of effective medications exist, and proper use of them is key."
 -0- 12/30/92
 ----
 NOTE TO EDITORS: Leading headache authorities are available for commentary and background information. For assistance in expediting these interviews, Please contact: Matt Lindley, Maree Gaetani or Jim Weinrebe of BBK, 617-734-4400.
 /CONTACT: Matt Lindley, Maree Gaetani, or Jim Weinrebe of BBK, 617- 734-4400 for Sandoz Pharmaceuticals/


CO: Sandoz Pharmaceutical ST: Massachusetts IN: MTC SU: PDT

CH -- NE002 -- 0529 12/30/92 09:03 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 30, 1992
Words:265
Previous Article:SOFTWARE ETC. BESTSELLING TITLES
Next Article:COURIER ELECTS JAMES F. CONWAY III CHIEF EXECUTIVE OFFICER
Topics:


Related Articles
STUDY POINTS TO NEW HOPE FOR MIGRAINE SUFFERERS IN 50-YEAR-OLD DRUG
UNIQUE NEW NASAL SPRAY FORM OF STADOL(R) ENTERS PRESCRIPTION PAIN RELIEF MARKET
BUTORPHANOL TARTRATE NASAL SPRAY OFFERS CONVENIENT THERAPY FOR TREATING MIGRAINE PAIN
NAUSEA REDUCED IN MIGRAINE PATIENTS FOLLOWING ADMINISTRATION OF DHE-45, STUDY SHOWS
MIGRAINE NASAL SPRAY PROVIDES SAFE, EFFECTIVE RELIEF OF HEADACHE PAIN AND NAUSEA, CONCLUDES RECENT STUDY AT UNIVERSITY OF KANSAS MEDICAL CENTER
MIGRAINE NASAL SPRAY PROVIDES SAFE, EFFECTIVE RELIEF OF HEADACHE PAIN AND NAUSEA, CONCLUDES RECENT STUDY AT UNIVERSITY OF KANSAS MEDICAL CENTER
Migraine Sufferers Experience Complete Headache Response With ZOMIG(R) (zolmitriptan).
Imitrex(R) (Sumatriptan Succinate) Tablets Now Available in an Innovative Formulation For Migraine Sufferers; New Formulation Designed to Rapidly...
Ortho-McNeil Pharmaceutical, Inc. Announces Early Termination of FTC Review For Rights to AXERT(R) for Migraine Headaches.
Ortho-McNeil Pharmaceutical, Inc. to Acquire Marketing Rights to AXERT(R) For Migraine Headaches.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters